Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acumen Pharmaceuticals Inc
(NQ:
ABOS
)
2.900
+0.090 (+3.20%)
Streaming Delayed Price
Updated: 11:18 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acumen Pharmaceuticals Inc
< Previous
1
2
Next >
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
August 06, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 29, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 28, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 11, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 07, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
April 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
March 26, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
March 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
March 19, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
March 12, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
March 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
February 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
February 01, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 07, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
November 06, 2023
Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
November 02, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
October 27, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
October 04, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
September 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.